Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
45,101,565
-
Total 13F shares
-
22,993,565
-
Share change
-
+2,760,707
-
Total reported value
-
$373,875,065
-
Put/Call ratio
-
129%
-
Price per share
-
$16.26
-
Number of holders
-
94
-
Value change
-
+$49,054,572
-
Number of buys
-
43
-
Number of sells
-
60
Institutional Holders of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) as of Q1 2024
As of 31 Mar 2024,
Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) was held by
94 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,993,565 shares.
The largest 10 holders included
BlackRock Inc., Paradigm Biocapital Advisors LP, Sofinnova Investments, Inc., VANGUARD GROUP INC, Polar Capital Holdings Plc, Point72 Asset Management, L.P., D. E. Shaw & Co., Inc., STATE STREET CORP, PICTET ASSET MANAGEMENT Holding SA, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
94
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.